File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Oral health status, oral microflora, and non-surgical periodontal treatment of renal transplant patients receiving cyclosporin A and FK506.

TitleOral health status, oral microflora, and non-surgical periodontal treatment of renal transplant patients receiving cyclosporin A and FK506.
Authors
Issue Date2000
PublisherRoyal Australasian College of Dental Surgeons. The Journal's web site is located at http://www.racds.org
Citation
Annals Of The Royal Australasian College Of Dental Surgeons, 2000, v. 15, p. 286-291 How to Cite?
AbstractOBJECTIVES: To determine the oral health status, oral microflora and the effect of non-surgical periodontal treatment on gingival overgrowth of renal allograft recipients receiving either cyclosporin A (CsA) or FK506 (Tacrolimus) as an immunosuppressant. MATERIALS AND METHODS: A total of 47 patients receiving CsA (mean age 43.1 years) and 10 receiving FK506 (mean age 40.1 years) were included in the study. Stone casts were taken for measurement of gingival overgrowth. An oral rinse technique was used to investigate the prevalence of yeasts, and aerobic and facultatively anaerobic Gram-negative rods (AGNR). RESULTS: The CsA and FK506 patients exhibited a Gingival Overgrowth Index (GOI) of 45.2%, and 25.1%, respectively (p < 0.05). The CsA patients had a GOI of 15.2% after one year of non-surgical periodontal treatment. The difference between pre- and postoperative gingival overgrowth indices was significant (p < 0.0001). Candida albicans and Klebsiella pneumoniae were the most notable yeast and AGRN found. CONCLUSIONS: Renal transplant patients, being immunocompromised, constitute a high-risk group for gingival overgrowth. However, the FK506 regime appeared to ameliorate this effect, compared with CsA. Non-surgical periodontal treatment was effective in reducing established gingival overgrowth in both CsA and FK506 patients (p < 0.05). Adequate pre- and post-transplant oral health care is recommended, for these patients, irrespective of the drug regime.
Persistent Identifierhttp://hdl.handle.net/10722/162438
ISSN
2015 SCImago Journal Rankings: 0.101

 

DC FieldValueLanguage
dc.contributor.authorChu, FCSen_HK
dc.contributor.authorTsang, PCSen_HK
dc.contributor.authorChan, AWKen_HK
dc.contributor.authorLeung, WKen_HK
dc.contributor.authorSamaranayake, LPen_HK
dc.contributor.authorChan, TMen_HK
dc.date.accessioned2012-09-05T05:19:55Z-
dc.date.available2012-09-05T05:19:55Z-
dc.date.issued2000en_HK
dc.identifier.citationAnnals Of The Royal Australasian College Of Dental Surgeons, 2000, v. 15, p. 286-291en_HK
dc.identifier.issn0158-1570en_HK
dc.identifier.urihttp://hdl.handle.net/10722/162438-
dc.description.abstractOBJECTIVES: To determine the oral health status, oral microflora and the effect of non-surgical periodontal treatment on gingival overgrowth of renal allograft recipients receiving either cyclosporin A (CsA) or FK506 (Tacrolimus) as an immunosuppressant. MATERIALS AND METHODS: A total of 47 patients receiving CsA (mean age 43.1 years) and 10 receiving FK506 (mean age 40.1 years) were included in the study. Stone casts were taken for measurement of gingival overgrowth. An oral rinse technique was used to investigate the prevalence of yeasts, and aerobic and facultatively anaerobic Gram-negative rods (AGNR). RESULTS: The CsA and FK506 patients exhibited a Gingival Overgrowth Index (GOI) of 45.2%, and 25.1%, respectively (p < 0.05). The CsA patients had a GOI of 15.2% after one year of non-surgical periodontal treatment. The difference between pre- and postoperative gingival overgrowth indices was significant (p < 0.0001). Candida albicans and Klebsiella pneumoniae were the most notable yeast and AGRN found. CONCLUSIONS: Renal transplant patients, being immunocompromised, constitute a high-risk group for gingival overgrowth. However, the FK506 regime appeared to ameliorate this effect, compared with CsA. Non-surgical periodontal treatment was effective in reducing established gingival overgrowth in both CsA and FK506 patients (p < 0.05). Adequate pre- and post-transplant oral health care is recommended, for these patients, irrespective of the drug regime.en_HK
dc.languageengen_US
dc.publisherRoyal Australasian College of Dental Surgeons. The Journal's web site is located at http://www.racds.orgen_HK
dc.relation.ispartofAnnals of the Royal Australasian College of Dental Surgeonsen_HK
dc.subject.meshAdulten_US
dc.subject.meshAgeden_US
dc.subject.meshCandida - Classificationen_US
dc.subject.meshCohort Studiesen_US
dc.subject.meshCyclosporine - Therapeutic Useen_US
dc.subject.meshDmf Indexen_US
dc.subject.meshEnterobacteriaceae - Classificationen_US
dc.subject.meshFollow-Up Studiesen_US
dc.subject.meshGingival Overgrowth - Chemically Induced - Classificationen_US
dc.subject.meshGram-Negative Aerobic Rods And Cocci - Classificationen_US
dc.subject.meshGram-Negative Facultatively Anaerobic Rods - Classificationen_US
dc.subject.meshHealth Statusen_US
dc.subject.meshHumansen_US
dc.subject.meshImmunocompromised Hosten_US
dc.subject.meshImmunosuppressive Agents - Therapeutic Useen_US
dc.subject.meshKidney Transplantationen_US
dc.subject.meshMiddle Ageden_US
dc.subject.meshMouth - Microbiologyen_US
dc.subject.meshOral Healthen_US
dc.subject.meshPeriodontal Diseases - Therapyen_US
dc.subject.meshPeriodontal Indexen_US
dc.subject.meshRisk Factorsen_US
dc.subject.meshStatistics As Topicen_US
dc.subject.meshTacrolimus - Therapeutic Useen_US
dc.subject.meshTransplantation, Homologousen_US
dc.titleOral health status, oral microflora, and non-surgical periodontal treatment of renal transplant patients receiving cyclosporin A and FK506.en_HK
dc.typeArticleen_HK
dc.identifier.emailChu, FCS: cschu@hkucc.hku.hken_HK
dc.identifier.emailTsang, PCS: csptsang@hkucc.hku.hken_HK
dc.identifier.emailChan, AWK: awkchan@hkucc.hku.hken_HK
dc.identifier.emailLeung, WK: ewkleung@hkucc.hku.hken_HK
dc.identifier.emailSamaranayake, LP: lakshman@hku.hkCen_HK
dc.identifier.emailChan, TM: dtmchan@hku.hk-
dc.identifier.authorityChu, FCS=rp00035en_HK
dc.identifier.authorityTsang, PCS=rp00026en_HK
dc.identifier.authorityLeung, WK=rp00019en_HK
dc.identifier.authoritySamaranayake, LP=rp00023en_HK
dc.identifier.authorityChan, TM=rp00394en_HK
dc.description.naturelink_to_subscribed_fulltexten_US
dc.identifier.pmid11709958-
dc.identifier.scopuseid_2-s2.0-0034303889en_HK
dc.identifier.hkuros57736-
dc.identifier.volume15en_HK
dc.identifier.spage286en_HK
dc.identifier.epage291en_HK
dc.publisher.placeAustraliaen_HK
dc.identifier.scopusauthoridChu, FC=7201881096en_HK
dc.identifier.scopusauthoridTsang, PC=7202936002en_HK
dc.identifier.scopusauthoridChan, AW=7403167849en_HK
dc.identifier.scopusauthoridLeung, WK=25224691800en_HK
dc.identifier.scopusauthoridSamaranayake, LP=7102761002en_HK
dc.identifier.scopusauthoridChan, TM=7402687700en_HK

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats